United States securities and exchange commission logo





                             January 7, 2022

       Chee Kong CHOO
       Director and Chairman
       CytoMed Therapeutics Pte. Ltd.
       21 Bukit Batok Crescent
       #17-80 WCEGA Tower
       Singapore 658065

                                                        Re: CytoMed
Therapeutics Pte. Ltd.
                                                            Amendment No. 1 to
Draft Registration Statement on Form F-1
                                                            Submitted November
19, 2021
                                                            CIK No. 0001873093

       Dear Mr. CHOO:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Amendment No. 2 to Draft Registration Statement on Form F-1 filed
December 20, 2021

       General

   1.                                                   Please provide us with
copies of all written communications, as defined in Rule 405 under
                                                        the Securities Act,
that you, or anyone authorized to do so on your behalf, present to
                                                        potential investors in
reliance on Section 5(d) of the Securities Act, whether or not they
                                                        retain copies of the
communications.
               We remind you that the company and its management are
responsible for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
       action by the staff.
 Chee Kong CHOO
CytoMed Therapeutics Pte. Ltd.
January 7, 2022
Page 2

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Tracie Mariner at 202-551-3744 or Daniel Gordon at
202-551-3486 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Abby Adams at 202-551-6902 or Celeste Murphy at 202-551-3257 with any
other
questions.



                                                           Sincerely,
FirstName LastNameChee Kong CHOO
                                                           Division of
Corporation Finance
Comapany NameCytoMed Therapeutics Pte. Ltd.
                                                           Office of Life
Sciences
January 7, 2022 Page 2
cc:       Richard I. Anslow, Esq.
FirstName LastName